Literature DB >> 26722291

Endostar enhances the antitumor effects of radiation by affecting energy metabolism and alleviating the tumor microenvironment in a Lewis lung carcinoma mouse model.

Yong-Fa Zheng1, Wei Ge1, Hui-Lin Xu1, DE-Dong Cao1, Liang Liu1, Ping-Po Ming1, Chang-Hu Li1, Xi-Ming Xu1, Wei-Ping Tao1, Ze-Zhang Tao2.   

Abstract

Lung cancer is a leading cause of morbidity and mortality. Previous studies have identified that an improvement in treatment efficacy was achieved using Endostar; however, the role of Endostar in lung cancer remains poorly understood. The present study investigated whether the enhanced antitumor effects of Endostar in combination with radiation involved changes in the metabolism and microenvironment in non-small cell lung cancer. A Lewis lung carcinoma mouse model was used, including the control, Endostar (ES), radiotherapy (RT) and Endostar plus radiotherapy (ES + RT) groups. The tumor inhibition rates and growth were described based on changes in tumor volume. In addition, ultraviolet enzymatic analysis was performed to determine the lactate level and reverse transcription-polymerase chain reaction was used to measure the mRNA expression of lactate dehydrogenase (LDH). A Meph-3 pH meter was used to detect the ranges of tumor interstitial tissue pH, and immunohistochemical analysis was adopted to examine hypoxia within the tumor microenvironment. The tumor inhibition rate of the ES + RT group was significantly higher compared with the other three groups (P<0.05). Following treatment, the lactate levels decreased in all three treatment groups compared with the control, particularly in the ES + RT group (P<0.05). Reduced LDH expression and hypoxic fraction in the tumor microenvironment were also observed in the ES + RT group (P<0.05). Furthermore, changes from acidic to alkaline pH in the tumor microenvironment were detected in the ES + RT group. The present study suggested that Endostar is involved in the regulation of metabolism and tumor microenvironment hypoxia, which may be responsible for the enhanced antitumor effect of Endostar in combination with radiotherapy.

Entities:  

Keywords:  endostar; hypoxia; lactate; lung cancer; radiotherapy

Year:  2015        PMID: 26722291      PMCID: PMC4665656          DOI: 10.3892/ol.2015.3679

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  37 in total

1.  On respiratory impairment in cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-08-10       Impact factor: 47.728

2.  Inhibition of radiation-induced DNA damage by jamun, Syzygium cumini, in the cultured splenocytes of mice exposed to different doses of γ-radiation.

Authors:  Ganesh Chandra Jagetia; Prakash Chandra Shetty; Mamidipudi Srinivasa Vidyasagar
Journal:  Integr Cancer Ther       Date:  2011-07-06       Impact factor: 3.279

3.  Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells.

Authors:  Ling Zhang; Wei Ge; Ke Hu; YanYan Zhang; ChangHu Li; XiMing Xu; Du He; ZhenYu Zhao; JinZhong Zhang; FangFang Jie; Yu Chen; YongFa Zheng
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

Review 4.  Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy.

Authors:  Pek Keng Koh; Corinne Faivre-Finn; Fiona H Blackhall; Dirk De Ruysscher
Journal:  Cancer Treat Rev       Date:  2011-12-22       Impact factor: 12.111

Review 5.  Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).

Authors:  Thanyanan Reungwetwattana; Saravut J Weroha; Julian R Molina
Journal:  Clin Lung Cancer       Date:  2011-12-08       Impact factor: 4.785

Review 6.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

Review 7.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

Review 8.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

9.  Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models.

Authors:  Fang Peng; Zumin Xu; Jin Wang; Yuanyuan Chen; Qiang Li; Yufang Zuo; Jing Chen; Xiao Hu; Qichao Zhou; Yan Wang; Honglian Ma; Yong Bao; Ming Chen
Journal:  PLoS One       Date:  2012-04-09       Impact factor: 3.240

10.  [Effects of rh-endostar in combination with radiotherapy on rats with lung cancer].

Authors:  He Du; Wei Ge; Changhu Li; Zhenyu Zhao; Ximin Xu; Fang Yang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-04
View more
  3 in total

1.  Heterogeneity of circulating tumor cell dissemination and lung metastases in a subcutaneous Lewis lung carcinoma model.

Authors:  Jessica E Fitzgerald; Brook K Byrd; Roshani A Patil; Rendall R Strawbridge; Scott C Davis; Chiara Bellini; Mark Niedre
Journal:  Biomed Opt Express       Date:  2020-06-08       Impact factor: 3.732

2.  Anti-tumor effect of local injectable hydrogel-loaded endostatin alone and in combination with radiotherapy for lung cancer.

Authors:  Na Wang; Qin Gao; Juan Tang; YiQing Jiang; LiShi Yang; XiangXiang Shi; Yue Chen; Yan Zhang; ShaoZhi Fu; Sheng Lin
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

3.  Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis.

Authors:  Meng Yuan; Yirui Zhai; Yu Men; Jianyang Wang; Lei Deng; Wenqing Wang; Yongxing Bao; Xu Yang; Shuang Sun; Zeliang Ma; Yunsong Liu; Jun Wang; Hui Zhu; Zhouguang Hui
Journal:  Thorac Cancer       Date:  2021-10-21       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.